These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27330280)

  • 1. Mode of administration of dulaglutide: implications for treatment adherence.
    Amblee A
    Patient Prefer Adherence; 2016; 10():975-82. PubMed ID: 27330280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
    Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
    J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
    Reaney M; Yu M; Lakshmanan M; Pechtner V; van Brunt K
    Diabetes Obes Metab; 2015 Sep; 17(9):896-903. PubMed ID: 26095190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
    Yu M; Van Brunt K; Varnado OJ; Boye KS
    Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.
    Matza LS; Boye KS; Currie BM; Paczkowski R; Lando LF; Mody R; Jordan J
    Curr Med Res Opin; 2018 Aug; 34(8):1457-1464. PubMed ID: 29661026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.
    Brown RE; Abitbol A; Bajaj HS; Goldenberg R; Khandwala H; Abdel-Salam S; Aronson R
    Diabetes Res Clin Pract; 2019 Oct; 156():107820. PubMed ID: 31446111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dulaglutide for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch
    Asakura T; Suzuki S; Aranishi T; Cai Z
    Curr Med Res Opin; 2018 Jun; 34(6):1117-1124. PubMed ID: 29504812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
    Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
    Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide: A Review in Type 2 Diabetes.
    Burness CB; Scott LJ
    BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
    Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T
    Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
    Boye KS; Sapin H; García-Pérez LE; Rosilio M; Orsini Federici M; Heitmann E; Jung H; Aigner U; Guerci B; Giorgino F; Norrbacka K
    Diabetes Ther; 2020 Oct; 11(10):2383-2399. PubMed ID: 32880876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.
    Nagaike H; Ohara M; Kohata Y; Hiromura M; Tomoyasu M; Takada M; Yamamoto T; Hayashi T; Fukui T; Hirano T
    Diabetes Ther; 2019 Feb; 10(1):215-228. PubMed ID: 30612316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.